{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:54Z","timestamp":1791563214111,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health and Welfare, Republic of Korea","award":["HA22C0012"],"award-info":[{"award-number":["HA22C0012"]}]},{"name":"Ministry of Health and Welfare, Republic of Korea","award":["HA22C0012"],"award-info":[{"award-number":["HA22C0012"]}]},{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["02-2020-0048"],"award-info":[{"award-number":["02-2020-0048"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in phase II clinical trial of a combination of eribulin and nivolumab for HER-2-negative metastatic breast cancer (MBC) (KORNELIA trial, NCT04061863).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analyzed associations between tumor molecular profiles based on genomic (<jats:italic>n<\/jats:italic>\u2009=\u200976) and transcriptomic data (<jats:italic>n<\/jats:italic>\u2009=\u200958) and therapeutic efficacy. Patients who achieved progression-free survival (PFS)\u2009\u2265\u20096\u00a0months were defined as PFS6-responders and PFS6-nonresponders otherwise.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>Analyses on tumor mutation burden (TMB) showed a tendency toward a favorable effect on efficacy, while several analyses related to homologous recombination deficiency (HRD) indicated a potentially negative impact on efficacy. Patients harboring <jats:italic>TP53<\/jats:italic> mutations showed significantly poor PFS6 rate and PFS, which correlated with the enrichment of cell cycle-related signatures in PFS6-nonresponders. High antigen presentation gene set enrichment scores (\u2265\u2009median) were significantly associated with longer PFS. Na\u00efve B-cell and plasma cell proportions were considerably higher in long responders (\u2265\u200918\u00a0months).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>Genomic features including TMB, HRD, and <jats:italic>TP53<\/jats:italic> mutations and transcriptomic features related to immune cell profiles and cell cycle may distinguish responders. Our findings provide insights for further exploring the combination regimen and its biomarkers in these tumors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00262-024-03782-7","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:08:23Z","timestamp":1722949703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Changhee","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyuk","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Sil","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Yeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"3782_CR1","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/nejmoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121. https:\/\/doi.org\/10.1056\/nejmoa1809615","journal-title":"N Engl J Med"},{"key":"3782_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/nejmoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/nejmoa2202809","journal-title":"N Engl J Med"},{"key":"3782_CR3","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21873\/anticanres.12541","volume":"38","author":"W Goto","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y et al (2018) Eribulin promotes antitumor immune responses in patients with locally advanced or metastatic breast cancer. Anticancer Res 38:2929\u20132938. https:\/\/doi.org\/10.21873\/anticanres.12541","journal-title":"Anticancer Res"},{"key":"3782_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S (2012) Eribulin\u2014a review of preclinical and clinical studies. Crit Rev Oncol Hematol 81:163\u2013184. https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.002","journal-title":"Crit Rev Oncol Hematol"},{"key":"3782_CR5","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","volume":"27","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Kalinsky K, Kaklamani VG et al (2021) Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib\/II study. Clin Cancer Res 27:3061\u20133068. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4726","journal-title":"Clin Cancer Res"},{"key":"3782_CR6","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2020.3524","volume":"6","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Barroso-Sousa R, Keenan T et al (2020) Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor-positive, ERBB2-negative metastatic breast cancer: a randomized clinical trial. JAMA Oncol 6:1598\u20131605. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3524","journal-title":"JAMA Oncol"},{"key":"3782_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113386","author":"SH Kim","year":"2023","unstructured":"Kim SH, Im S, Suh KJ et al (2023) Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: a phase IB\/II study (KCSG BR18-16). Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2023.113386","journal-title":"Eur J Cancer"},{"key":"3782_CR8","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1038\/s41467-021-25769-z","volume":"12","author":"TE Keenan","year":"2021","unstructured":"Keenan TE, Guerriero JL, Barroso-Sousa R et al (2021) Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun 12:5563. https:\/\/doi.org\/10.1038\/s41467-021-25769-z","journal-title":"Nat Commun"},{"key":"3782_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.11809","volume":"3","author":"P-S Kok","year":"2020","unstructured":"Kok P-S, Cho D, Yoon W-H et al (2020) Validation of progression-free survival rate at 6 months and objective response for estimating overall survival in immune checkpoint inhibitor trials. JAMA Netw Open 3:e2011809. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.11809","journal-title":"JAMA Netw Open"},{"key":"3782_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12064-012-0162-3","volume":"131","author":"GP Wagner","year":"2012","unstructured":"Wagner GP, Kin K, Lynch VJ (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci 131:281\u2013285. https:\/\/doi.org\/10.1007\/s12064-012-0162-3","journal-title":"Theory Biosci"},{"key":"3782_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-10284-1","volume":"22","author":"L Ke","year":"2022","unstructured":"Ke L, Li S, Cui H (2022) The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. BMC Cancer 22:1\u201312. https:\/\/doi.org\/10.1186\/s12885-022-10284-1","journal-title":"BMC Cancer"},{"key":"3782_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/nejmoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382:2091\u20132102. https:\/\/doi.org\/10.1056\/nejmoa1911440","journal-title":"N Engl J Med"},{"key":"3782_CR13","doi-asserted-by":"publisher","first-page":"e1526","DOI":"10.1002\/onco.13829","volume":"26","author":"MR Toh","year":"2021","unstructured":"Toh MR, Ngeow J (2021) Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist 26:e1526\u2013e1537. https:\/\/doi.org\/10.1002\/onco.13829","journal-title":"Oncologist"},{"key":"3782_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nsmb.3252","volume":"23","author":"J Michl","year":"2016","unstructured":"Michl J, Zimmer J, Buffa FM et al (2016) FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat Struct Mol Biol 23:755\u2013757. https:\/\/doi.org\/10.1038\/nsmb.3252","journal-title":"Nat Struct Mol Biol"},{"key":"3782_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1200\/JCO.2020.38.4_suppl.732","volume":"38","author":"AE Chang","year":"2020","unstructured":"Chang AE, Zhen DB, Radke M et al (2020) Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): a single institution experience. J Clin Oncol 38:732. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.732","journal-title":"J Clin Oncol"},{"key":"3782_CR16","doi-asserted-by":"publisher","first-page":"W102","DOI":"10.1093\/nar\/gky406","volume":"46","author":"J Lee","year":"2018","unstructured":"Lee J, Lee AJ, Lee J-K et al (2018) Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures. Nucleic Acids Res 46:W102\u2013W108. https:\/\/doi.org\/10.1093\/nar\/gky406","journal-title":"Nucleic Acids Res"},{"key":"3782_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero F, Joshi T, Marquard AM et al (2015) Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann Oncol 26:64\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdu479","journal-title":"Ann Oncol"},{"key":"3782_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41523-018-0066-6","volume":"4","author":"Z Sztupinszki","year":"2018","unstructured":"Sztupinszki Z, Diossy M, Krzystanek M et al (2018) Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer 4:8\u201311. https:\/\/doi.org\/10.1038\/s41523-018-0066-6","journal-title":"NPJ Breast Cancer"},{"key":"3782_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12864-019-5849-0","volume":"20","author":"AC Picornell","year":"2019","unstructured":"Picornell AC, Echavarria I, Alvarez E et al (2019) Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. BMC Genomics 20:452. https:\/\/doi.org\/10.1186\/s12864-019-5849-0","journal-title":"BMC Genomics"},{"key":"3782_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211","journal-title":"Nat Protoc"},{"key":"3782_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102:15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci"},{"key":"3782_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H et al (2015) The molecular signatures database hallmark gene set collection. Cell Syst 1:417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004","journal-title":"Cell Syst"},{"key":"3782_CR23","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"VV Thorsson","year":"2018","unstructured":"Thorsson VV, Gibbs DL, Brown SD et al (2018) The immune landscape of cancer. Immunity 48:812-830.e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023","journal-title":"Immunity"},{"key":"3782_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457. https:\/\/doi.org\/10.1038\/nmeth.3337","journal-title":"Nat Methods"},{"key":"3782_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng D, Ye Z, Shen R et al (2021) IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol 12:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2021.687975","journal-title":"Front Immunol"},{"key":"3782_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/po.16.00031","author":"WD den Brok","year":"2017","unstructured":"den Brok WD, Schrader KA, Sun S et al (2017) Homologous recombination deficiency in breast cancer: a clinical review. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/po.16.00031","journal-title":"JCO Precis Oncol"},{"key":"3782_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J et al (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47\u201354. https:\/\/doi.org\/10.1038\/nature17676","journal-title":"Nature"},{"key":"3782_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"PS Bernard","year":"2009","unstructured":"Bernard PS, Parker JS, Mullins M et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160\u20131167. https:\/\/doi.org\/10.1200\/JCO.2008.18.1370","journal-title":"J Clin Oncol"},{"key":"3782_CR29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan TA, Yarchoan M, Jaffee E et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30:44\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdy495","journal-title":"Ann Oncol"},{"key":"3782_CR30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509\u20132520. https:\/\/doi.org\/10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"3782_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214\u2013218. https:\/\/doi.org\/10.1038\/nature12213","journal-title":"Nature"},{"key":"3782_CR32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","volume":"21","author":"RM Chabanon","year":"2021","unstructured":"Chabanon RM, Rouanne M, Lord CJ et al (2021) Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer 21:701\u2013717. https:\/\/doi.org\/10.1038\/s41568-021-00386-6","journal-title":"Nat Rev Cancer"},{"key":"3782_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cjp2.271","volume":"8","author":"J Budczies","year":"2022","unstructured":"Budczies J, Kluck K, Beck S et al (2022) Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. J Pathol: Clin Res 8:371\u2013382. https:\/\/doi.org\/10.1002\/cjp2.271","journal-title":"J Pathol: Clin Res"},{"key":"3782_CR34","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.7150\/ijbs.79654","volume":"19","author":"D Yang","year":"2023","unstructured":"Yang D, Huang F-X, Wei W et al (2023) Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer. Int J Biol Sci 19:1846\u20131860. https:\/\/doi.org\/10.7150\/ijbs.79654","journal-title":"Int J Biol Sci"},{"key":"3782_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01018-0","volume":"8","author":"CY Ock","year":"2017","unstructured":"Ock CY, Hwang JE, Keam B et al (2017) Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun 8:1\u201312. https:\/\/doi.org\/10.1038\/s41467-017-01018-0","journal-title":"Nat Commun"},{"key":"3782_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.795401","volume":"12","author":"Y Gan","year":"2022","unstructured":"Gan Y, Li X, Han S et al (2022) The cGAS\/STING pathway: a novel target for cancer therapy. Front Immunol 12:1\u201315. https:\/\/doi.org\/10.3389\/fimmu.2021.795401","journal-title":"Front Immunol"},{"key":"3782_CR37","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/ng.3441","volume":"47","author":"LB Alexandrov","year":"2015","unstructured":"Alexandrov LB, Jones PH, Wedge DC et al (2015) Clock-like mutational processes in human somatic cells. Nat Genet 47:1402\u20131407. https:\/\/doi.org\/10.1038\/ng.3441","journal-title":"Nat Genet"},{"key":"3782_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-018-1044-5","volume":"20","author":"NA Ungerleider","year":"2018","unstructured":"Ungerleider NA, Rao SG, Shahbandi A et al (2018) Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. Breast Cancer Res 20:115. https:\/\/doi.org\/10.1186\/s13058-018-1044-5","journal-title":"Breast Cancer Res"},{"key":"3782_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.98","volume":"10","author":"S Jiang","year":"2020","unstructured":"Jiang S, He Y, Li M, Wang X (2020) Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers. Clin Transl Med 10:e98. https:\/\/doi.org\/10.1002\/ctm2.98","journal-title":"Clin Transl Med"},{"key":"3782_CR40","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/cancers12092661","volume":"12","author":"M Ullah","year":"2020","unstructured":"Ullah M, Aoudjeghout W, Pimpie C et al (2020) Mitosis in cancer cell increases immune resistance via high expression of HLA-G and PD-L1. Cancers (Basel) 12:2661","journal-title":"Cancers (Basel)"},{"key":"3782_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22300-2","volume":"12","author":"Q Hu","year":"2021","unstructured":"Hu Q, Hong Y, Qi P et al (2021) Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. Nat Commun 12:1\u201313. https:\/\/doi.org\/10.1038\/s41467-021-22300-2","journal-title":"Nat Commun"},{"key":"3782_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"key":"3782_CR43","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.3390\/ijms22094597","volume":"22","author":"N Vahidfar","year":"2021","unstructured":"Vahidfar N, Aghanejad A, Ahmadzadehfar H et al (2021) Theranostic advances in breast cancer in nuclear medicine. Int J Mol Sci 22:4597. https:\/\/doi.org\/10.3390\/ijms22094597","journal-title":"Int J Mol Sci"},{"key":"3782_CR44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s11307-022-01795-1","volume":"25","author":"P Siminzar","year":"2023","unstructured":"Siminzar P, Tohidkia MR, Eppard E et al (2023) Recent trends in diagnostic biomarkers of tumor microenvironment. Mol Imaging Biol 25:464\u2013482. https:\/\/doi.org\/10.1007\/s11307-022-01795-1","journal-title":"Mol Imaging Biol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03782-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:07:51Z","timestamp":1726510071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03782-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3782"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03782-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seung-Jae Noh, Inkyung Shin, and Dae-Yeon Cho are employees of PentaMedix Co., Ltd. There are no other conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The trial protocol and all amendments were approved by the institutional review boards (IRB) of the participating institutions, including Seoul National University Bundang Hospital (IRB No. B-1811-505-004). The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The funders had no role in any of the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of funders"}}],"article-number":"197"}}